Engineered extracellular vesicles (EVs): Promising diagnostic/therapeutic tools for pediatric high-grade glioma - 23/05/23
, Xinjun Wang b, c, h, ⁎ 
Abstract |
Diffuse intrinsic pontine glioma (DIPG) is a highly malignant brain tumor that mainly occurs in children with extremely low overall survival. Traditional therapeutic strategies, such as surgical resection and chemotherapy, are not feasible mostly due to the special location and highly diffused features. Radiotherapy turns out to be the standard treatment method but with limited benefits of overall survival. A broad search for novel and targeted therapies is in the progress of both preclinical investigations and clinical trials. Extracellular vesicles (EVs) emerged as a promising diagnostic and therapeutic candidate due to their distinct biocompatibility, excellent cargo-loading-delivery capacity, high biological barrier penetration efficiency, and ease of modification. The utilization of EVs in various diseases as biomarker diagnoses or therapeutic agents is revolutionizing modern medical research and practice. In this review, we will briefly talk about the research development of DIPG, and present a detailed description of EVs in medical applications, with a discussion on the application of engineered peptides on EVs. The possibility of applying EVs as a diagnostic tool and drug delivery system in DIPG is also discussed.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The prognosis of pediatric diffuse intrinsic pontine glioma (DIPG) remains to be improved. |
• | Novel recognition and treatment for DIPG require overcoming complex situations. |
• | EVs play an important role in multiple brain diseases. |
• | EV application can be a future direction of DIPG diagnosis and therapy. |
• | EVs may act as biomarkers for detection and vehicles for drug delivery. |
Keywords : Diffuse intrinsic pontine glioma (DIPG), Extracellular vesicles (EVs), Engineered modification, Early diagnosis, Targeted therapy
Plan
Vol 163
Article 114630- juillet 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
